Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis - Takeaways - MDSpire

Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis

  • By

  • Rui He

  • Limin Huang

  • Yang Chen

  • Minqi Liu

  • Miaomiao Xie

  • Honglei Yuan

  • Ling Mao

  • January 3, 2026

  • 0 min

Share

  • 1

    Silicosis is a progressive lung disease caused by inhaling crystalline silica, leading to chronic inflammation and irreversible fibrosis.

  • 2

    Complicated silicosis is characterized by large coalescent nodules and is associated with rapid progression and higher mortality rates.

  • 3

    Current diagnostic methods for silicosis have limitations, highlighting the need for non-invasive serum biomarkers for early detection.

  • 4

    Krebs von den Lungen-6 (KL-6) is a promising biomarker linked to disease severity in silicosis, but its role across disease stages is underexplored.

  • 5

    This study evaluates serum KL-6 levels and their association with immune-inflammatory markers to improve early diagnosis and risk stratification.

Original Source(s)

Combination of Serum KL-6 and Immune/Inflammatory Markers for Identifying Complicated Silicosis

  • by Rui He, Limin Huang, Yang Chen, Minqi Liu, Miaomiao Xie, Honglei Yuan, Ling Mao

  • January 3, 2026

Related Content

Comparative efficacy of single exercise interventions on pulmonary function and quality of life in patients with chronic obstructive pulmonary disease: a systematic review and network meta-analysis

Botulinum Toxin Evaluated in Digital Ischemia

Individual-level meta-analysis examines response, dosing, and safety across ischemic etiologies

FDA Clears Breztri for Asthma Use

Single-inhaler triple therapy improved lung function vs dual therapy in phase 3 trials and showed rapid onset without new safety signals.